InterAx Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 14
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $2.81M
Latest Deal Amount
  • Investors
  • 9

InterAx General Information

Description

Developer of a drug discovery platform created to reduce the time and costs for the discovery and development of new drugs for a wide array of human diseases. The company offers to combine in-vitro cell signaling experiments with mathematical modeling of signaling pathways and machine learning to discover new effective treatments and de-risk clinical trials, thereby enabling the pharmaceutical industry to streamline the critical processes of drug candidate design and selection and then reducing the risks, costs, and duration of drug discovery and development of new drugs.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Primary Office
  • Park Innovaare
  • 5234 Villigen
  • Switzerland

InterAx Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

InterAx Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 25-Nov-2019 $2.81M 00.000 Completed Pre-Clinical Trials
6. Accelerator/Incubator 11-Oct-2019 00.000 00.000 Completed Pre-Clinical Trials
5. Seed Round 15-Jan-2019 00.000 00.000 000.00 Completed Pre-Clinical Trials
4. Seed Round 23-Dec-2016 00000 Completed Startup
3. Grant 21-Oct-2016 000.00 00000 Completed Startup
2. Accelerator/Incubator 01-Jan-2016 $130K $130K Completed Startup
1. Grant 01-Aug-2014 $167K Completed Startup
To view InterAx’s complete valuation and funding history, request access »

InterAx Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 000,000 00.000000 00.00 00.00 00 00.00 00.000
To view InterAx’s complete cap table history, request access »

InterAx Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of a drug discovery platform created to reduce the time and costs for the discovery and development of new dru
Discovery Tools (Healthcare)
Villigen, Switzerland
14 As of 2021
00.000
0000000000 00.000

00000000

e velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000 000000000
Utrecht, Netherlands
00 As of 0000
00.00
00.00 0000-00-00
000000&0 00.00

0000

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
000000000 00000 (0000000000)
San Mateo, CA
00 As of 0000
000.00
000000&0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

InterAx Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CrossBeta Biosciences Formerly VC-backed Utrecht, Netherlands 00 00.00 000000&0 00.00
0000 Formerly VC-backed San Mateo, CA 00 000.00 000000&0 000.00
00000000 Private Equity-Backed Holliston, MA 00 000.00 000000000 - 000.00
000000 00000000000 Formerly VC-backed Watertown, MA 00 00000 00000000 00000
000000 0000 000000 Pending Transaction (PE) Park City, UT 0 0000 0000000 0000 0000
You’re viewing 5 of 13 competitors. Get the full list »

InterAx Executive Team (7)

Name Title Board Seat Contact Info
Aurélien Rizk Ph.D Co-Founder, Chief Executive Officer & Board Member
Luca Zenone Co-Founder, Chief Operating Officer, Chief Financial Officer and Board Member
Gebhard Schertler Co-Founder & Scientific Advisor
Claudio Neto Scientific Advisor
You’re viewing 4 of 7 executive team members. Get the full list »

InterAx Board Members (5)

Name Representing Role Since
Aurélien Rizk Ph.D InterAx Co-Founder, Chief Executive Officer & Board Member 000 0000
Bettina Ernst Ph.D BERNINA BioInvest Board Member 000 0000
Jens Gobrecht Self Chairman 000 0000
Yiannis Monovoukas Ph.D Falcon III Ventures Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

InterAx Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

InterAx Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Horizon 2020 Government 000 0000 000000 0
EIC Accelerator Accelerator/Incubator 000 0000 000000 0
BERNINA BioInvest Venture Capital Minority 000 0000 000000 0
Falcon III Ventures Venture Capital Minority 000 0000 000000 0
Lichtsteiner Foundation Accelerator/Incubator Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »